Display options
Cite
Bachmann G, Kopacz S. Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin. Patient Prefer Adherence. 2009;3:259-64doi: 10.2147/ppa.s3901.
Bachmann, G., & Kopacz, S. (2009). Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin. Patient preference and adherence, 3259-64. https://doi.org/10.2147/ppa.s3901
Bachmann, Gloria, and Kopacz, Sharon. "Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin." Patient preference and adherence vol. 3 (2009): 259-64. doi: https://doi.org/10.2147/ppa.s3901
Bachmann G, Kopacz S. Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin. Patient Prefer Adherence. 2009 Nov 03;3:259-64. doi: 10.2147/ppa.s3901. PMID: 19936169; PMCID: PMC2778416.
Copy Download .nbib Format: NLM
Share it on

Patient Prefer Adherence. 2009 Nov 03;3:259-64. doi: 10.2147/ppa.s3901.

Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin.

Patient preference and adherence

Gloria Bachmann, Sharon Kopacz

Affiliations

  1. Women's Health Institute, University of Medicine and Dentistry of New Jersey, USA.

PMID: 19936169 PMCID: PMC2778416 DOI: 10.2147/ppa.s3901

Abstract

The combined oral contraceptive pill (COC) consisting of drospirenone 3 mg/ethinyl estradiol 20 mug (3 mg DRSP/20 mug EE-24/4) supplies 24 days of pills with hormones followed by 4 days of hormone-free pills. This regimen is called the 24/4 regimen. The progesterone component of this oral contraceptive pill (OCP), drospirenone (DRSP), is a fourth-generation progestin that has potent progestogenic, antimineralocorticoid, and antiandrogenic activity, which are unique characteristics compared with the other progestogens contained in most of the other OCPs currently marketed. This formulation, in addition to being an effective long-term OCP, has the additional medical benefit of providing a good parallel treatment for premenstrual dysphoric disorder and moderate acne. The effectiveness of 3 mg DRSP/20 mug EE-24/4, its tolerability and safety, and its additional non-contraceptive benefits are discussed.

Keywords: acne vulgaris; antiandrogenic activity; antimineralocorticoid activity; contraception; drospirenone; premenstrual dysphoric disorder

References

  1. Contraception. 2005 Jun;71(6):409-16 - PubMed
  2. Contraception. 2004 Sep;70(3):191-8 - PubMed
  3. Drugs. 2007;67(12):1749-65 - PubMed
  4. Contraception. 2005 Dec;72(6):414-21 - PubMed
  5. Contraception. 2008 Apr;77(4):249-56 - PubMed
  6. Adv Data. 2004 Dec 10;(350):1-36 - PubMed
  7. Clin Drug Investig. 2006;26(3):143-50 - PubMed
  8. Int Clin Psychopharmacol. 2000 Nov;15 Suppl 3:S5-17 - PubMed
  9. Fertil Steril. 2007 Jul;88(1):113-7 - PubMed
  10. Maturitas. 2008 Jun 20;60(2):78-91 - PubMed
  11. Obstet Gynecol. 2005 Sep;106(3):492-501 - PubMed

Publication Types